Finlay Vaccine Institute

21 Avenue, No. 19810, b/ 198 and 200, Atabey
21 Avenue
Postal code
(+53)72080976; (+53)72086086
Contact person's name
Indira Utria Torres (Head of the Business Department)
Short description of the company
Finlay Institute was founded in 1991. After more than 20 years of work in the field of vaccines, it merged with the Center for Biomolecular Chemistry, forming the current Finlay Vaccine Institute, a leading institution in this field in Cuba. This organization belongs to BioCubaFarma, a Group made up of institutions that carry out biotechnological and other high-tech research, in addition to the industrial production of medicines and other products in the country, as well as their commercialization. The corporate purpose of the Finlay Vaccine Institute is to produce and market pharmaceutical, biological, biotechnological or chemically synthesized preparations for use, fundamentally as a vaccine. The company has a closed cycle platform (research - development - production - marketing and post-sales monitoring) to obtain products aimed at solving health problems of the Cuban population and worldwide. It has a product portfolio of vaccines for pediatric and adult immunization. Currently, Soberanas COVID-19 vaccines stand out among the products of the Finlay Vaccines Institute.
Company`s description
Finlay Vaccine Institute's mission is to research, develop, produce, evaluate, negotiate and commercialize knowledge, technologies and products, mainly vaccines; directing all its technological, human and financial resources inorder to enhance the Advanced Vaccine Program, economic growth and development and the quality of life of the Cuban population. Finlay Vaccine Institute's vision is to be recognized as one of the high-tech companies, with high and growing levels of efficiency and quality standards in its technologies and products, mainly vaccines, effectively contributing to economic development and connected to the advanced vaccine program that the country requires. Finlay Vaccine Institute has developed a portfolio of products based on conventional and innovative vaccines, with a stable production to satisfy the national and export markets. The production system is supported by the technological capabilities of obtaining outer membrane vesicles, inactivated whole cells, toxoids, capsular polysaccharides, chemical synthesis and conjugation of macromolecules as fundamental assets. The Finlay Vaccine Institute product portfolio is made up of: Finished products: • SOBERANA® 02, RBD - Tetanus Toxoid conjugate COVID-19 vaccine • SOBERANA® Plus, RBD dimer COVID-19 vaccine • VA-MENGOC-BC®, Meningococcal BC vaccine • vax-MEN-ACW®135, ACW135 polysaccharide meningococcal vaccine • vax-SPIRAL®, trivalent leptospirosis vaccine • vax-TyVi®, Vi polysaccharide typhoid vaccine • vax-TET® 5, tetanus vaccine 5 Lf. • diTe-vax®, tetanus diphtheria vaccine for adults • VA-DIFTET®, tetanus diphtheria vaccine for pediatric use Active Pharmaceutical Ingredients: • Sterile Purified Tetanus Toxoid • Sterile Purified Diphtheria Toxoid • Inactivated cells of Bordetella pertussis • Vi Capsular Purified Polysaccharide of Salmonella Typhi • Active raw material of polysaccharide of Neisseria meningitidisA • Active raw material of polysaccharide of Neisseria meningitidisB • Purified polysaccharide of Neisseria meningitidis W135 • Outer membrane vesicles of Neisseria meningitidisB The next product launches will be: • SOBERANA® 01, COVID-19 vaccine based on SARS-CoV-2 RBD dimer and Neisseria meningitidis B outer membrane vesicles • Qumi-Vio®, 7-valent pneumococcal conjugate vaccine To read more:
Partner search
• Companies interested in venture investments • Scientific institutions with experience in R&D and clinical studies • Companies interested in vaccine projects • Commercial distributors
Short content description
Our company is interested in scientific collaboration for the development of innovative products, business with venture investments, business models such as co-development, commercial distribution, technology transfer, joint venture and other partnerships.
The programme is co-financed by the Slovenian Enterprise Fund and the European Union, namely from the European Fund for Regional Development. It is carried out on the basis of the Substantial Support of Fund Recipients (SME) programme from 2018 to 2023 within the framework of the Operational Programme for the Implementation of European Cohesion Policy from 2014 to 2020.